Guideline Statements
指南荟萃
Evaluation and Diagnosis 评估和诊断
1. Men presenting with symptoms of ED should undergo a thorough medical, sexual, and psychosocial history; a physical examination; and selective laboratory testing. (Clinical Principle)
1. 出现ED症状的男性应该有完整的医学、性和心理社会病史;体格检查;以及选择性实验室检测。(临床原则)
2. For the man with ED, validated questionnaires are recommended to assess the severity of ED, to measure treatment effectiveness, and to guide future management. (Expert Opinion)
2. 对于ED患者，建议使用有效问卷来评估ED的严重程度，衡量治疗效果，并指导未来的管理。(专家意见)
3. Men should be counseled that ED is a risk marker for underlying cardiovascular disease (CVD) and other health conditions that may warrant evaluation and treatment. (Clinical Principle)
3. 应告知男性ED是潜在心血管疾病（CVD）和其他健康状况的风险标志，可能需要评估和治疗。 (临床原则)
4. In men with ED, morning serum total testosterone levels should be measured. (Moderate Recommendation; Evidence Level: Grade C)
4. 在患有ED的男性中，应测量早晨血清总睾酮水平。(中等推荐;证据等级：C级)
5. For some men with ED, specialized testing and evaluation may be necessary to guide treatment. (Expert Opinion)
5. 对于一些患有ED的男性，可能需要进行专门的检测和评估来指导治疗。(专家意见)
Treatment 治疗
6. For men being treated for ED, referral to a mental health professional should be considered to promote treatment adherence, reduce performance anxiety, and integrate treatments into a sexual relationship. (Moderate Recommendation; Evidence Level: Grade C)
6. 对于接受ED治疗的男性，应考虑转诊至心理健康专家，以促进治疗的依从性，减少焦虑表现，并将治疗纳入其性关系中。(中等推荐;证据等级：C级)
7. Clinicians should counsel men with ED who have comorbidities known to negatively affect erectile function that lifestyle modifications, including changes in diet and increased physical activity, improve overall health and may improve erectile function. (Moderate Recommendation; Evidence Level: Grade C)
7. 临床医生应该建议患有ED的男性，如果他们患有已知的对勃起功能有负面影响的共患病，那么生活方式的改变，包括饮食的改变和增加身体活动，可以改善整体健康，并可能改善勃起功能。(中等推荐;证据级别：C级)
8. Men with ED should be informed regarding the treatment option of an FDA-approved oral phosphodiesterase type 5 inhibitor (PDE5i), including discussion of benefits and risks/burdens, unless contraindicated. (Strong Recommendation; Evidence Level: Grade B)
8. 对于ED患者，应告知FDA批准的口服磷酸二酯酶5型抑制剂（PDE5i）的治疗选择，包括益处和风险/负担，除非有禁忌症。(强烈推荐;证据级别：B级)
9. When men are prescribed an oral PDE5i for the treatment of ED, instructions should be provided to maximize benefit/efficacy. (Strong Recommendation; Evidence Level: Grade C)
9. 当男性口服PDE5i治疗ED时，应提供指导以达到最大限度的益处/功效。(强烈建议;证据等级:C级)
10. For men who are prescribed PDE5i, the dose should be titrated to provide optimal efficacy. (Strong Recommendation; Evidence Level: Grade B)
10. 对于服用PDE5i的男性，应滴定剂量以提供最佳疗效。(强烈建议;证据等级:B级)
11. Men who desire preservation of erectile function after treatment for prostate cancer by radical prostatectomy (RP) or radiotherapy (RT) should be informed that early use of PDE5i post-treatment may not improve spontaneous, unassisted erectile function. (Moderate Recommendation; Evidence Level: Grade C)
11. 因前列腺癌行根治性前列腺切除术或放疗后的需要保留勃起功能的患者，应告知其早期使用PDE5i治疗后可能无法改善自发的、独立的勃起功能。(中等推荐;证据级别：C级)
12. Men with ED and testosterone deficiency (TD) who are considering ED treatment with a PDE5i should be informed that PDE5i may be more effective if combined with testosterone therapy. (Moderate Recommendation; Evidence Level: Grade C)
12. 正在用PDE5i进行ED治疗的患者，如果患有睾酮缺乏症（TD），与睾酮联合使用，PDE5i可能更有效。(中等推荐;证据等级：C级)
13. Men with ED should be informed regarding the treatment option of a vacuum erection device (VED), including discussion of benefits and risks/burdens. (Moderate Recommendation; Evidence Level: Grade C)
13. 应告知ED患者真空负压勃起装置（VED）的治疗方案，包括益处和风险/负担。(中等推荐;证据级别：C级)
14. Men with ED should be informed regarding the treatment option of intraurethral (IU) alprostadil, including discussion of benefits and risks/burdens. (Conditional Recommendation; Evidence Level: Grade C)
14. 应告知ED患者关于尿道内（IU）注射前列地尔的治疗方案，包括益处和风险/负担。(有条件推荐;证据级别：C级)
15. For men with ED who are considering the use of IU alprostadil, an in-office test should be performed. (Clinical Principle)
15. 对于考虑使用尿道内注射前列地尔的ED患者，应进行诊室内检查。(临床原则)
16. Men with ED should be informed regarding the treatment option of intracavernosal injections (ICI), including discussion of benefits and risks/burdens. (Moderate Recommendation; Evidence Level: Grade C)
16. 应告知ED患者阴茎海绵体内注射（ICI）的治疗方案，包括益处和风险/负担的。(中等推荐;证据级别：C级)
17. For men with ED who are considering ICI therapy, an in-office injection test should be performed. (Clinical Principle)
17. 对于考虑进行阴茎海绵体内注射治疗的ED患者，应进行室内注射试验。(临床原则)
18. Men with ED should be informed regarding the treatment option of penile prosthesis implantation, including discussion of benefits and risks/burdens. (Strong Recommendation; Evidence Level: Grade C)
18. 应告知ED患者关于阴茎假体植入的治疗方案，包括益处和风险/负担。(强烈推荐;证据级别：C级)
19. Men with ED who have decided on penile implantation surgery should be counseled regarding post-operative expectations. (Clinical Principle)
19. 对于决定进行阴茎假体植入手术的ED患者，应该询问其关于对手术后的期望。(临床原则)
20. Penile prosthetic surgery should not be performed in the presence of systemic, cutaneous, or urinary tract infection. (Clinical Principle)
20. 阴茎假体植入手术不应在全身、皮肤或泌尿道感染的情况下进行。(临床原则)
21. For young men with ED and focal pelvic/penile arterial occlusion and without documented generalized vascular disease or veno-occlusive dysfunction, penile arterial reconstruction may be considered. (Conditional Recommendation; Evidence Level: Grade C)
21. 对于患有ED和局灶性盆腔/阴茎动脉闭塞的年轻男性，如果没有全身性血管疾病或静脉闭塞性功能障碍，可考虑进行阴茎动脉重建。(有条件的推荐;证据级别：C级)
22. For men with ED, penile venous surgery is not recommended. (Moderate Recommendation; Evidence Level: Grade C)
22. 对于ED患者，不建议进行阴茎静脉手术。(中等推荐;证据级别：C级)
23. For men with ED, low-intensity extracorporeal shock wave therapy (ESWT) should be considered investigational. (Conditional Recommendation; Evidence Level: Grade C)
23. 对于ED患者，应将低强度体外冲击波治疗（ESWT）视为研究性治疗。(有条件的推荐;证据级别：C级)
24. For men with ED, intracavernosal stem cell therapy should be considered investigational. (Conditional Recommendation; Evidence Level: Grade C)
24. 对于ED患者，海绵体内干细胞治疗应该被认为是研究性治疗。(有条件的推荐;证据级别：C级)
25. For men with ED, platelet-rich plasma (PRP) therapy should be considered experimental. (Expert Opinion)
25. 对于ED患者，富血小板血浆（PRP）治疗应视为实验性治疗。(专家意见)
联系客服
